Leading in Cardiovascular
Tissue Engineering

We are a biotechnology company focused on the development and production of innovative biological medical devices. Our cell-free implants are designed to reduce the need for long-term medication, thereby minimizing the risk of adverse side effects. This approach offers a significant improvement in quality of life, especially for younger patients.
More Than
0
Years in Business
Available in More Than
0
Countries
More than
10000
Implants Worldwide

Technology

Auto Tissue Berlin utilises a proprietary and patented process entirely free of glutaraldehyde to decellularise and sterilise biological tissue. The durability of decellularised tissue has consistently been shown to surpass that of glutaraldehyde-treated tissue, with particularly notable benefits in the paediatric population.
Read more...

Contract Manufacturing

The Auto Tissue Berlin GmbH also offers contract research and manufacturing services for a wide range of biological tissues, and provides comprehensive support in the engineering, design, and prototyping of cardiovascular devices.

Read more...

Products

The Matrix Patch™ equine is a cell-free pericardial patch designed for vascular reconstruction and the repair of cardiac defects. It is primarily utilised in paediatric cardiac surgery and adult aortic valve repair procedures.

Read more...

Latest News

May 9, 2025

AATS 2025: Reimagining Tetralogy of Fallot Repair

At the 2025 AATS meeting, Dr. Osman Al Radi from Jeddah, Saudi-Arabia, presented a valve-sparing alternative for TOF patients using a tailored bicuspid valve with the Matrix Patch equine, showing early results comparable to standard repairs and potential long-term benefits.

Read more ...

March 7, 2024

ProFIT Project ‘Decellularised Stented Heart Valve (DGH)’

Exciting news! Our latest project, ‘Decellularized Stented Heart Valve (DGH)’, funded by the Berlin Senate and the EU, aims to revolutionise cardiovascular care. By developing a decellularised stented surgical aortic valve, we offer an innovative alternative to glutaraldehyde-treated valves, promising improved hydrodynamics and reduced patient risks.

Read more ...

December 11, 2023

New publication: 20-Year follow-up and comparison of valved conduits used for right ventricular outflow tract reconstruction.

Fadi Sabateen from the Department of Pediatric Cardiac Surgery, Children’s Heart Centre, National Institute of Cardiovascular Diseases, Bratislava, Slovakia published today a new report on the 20-Year follow-up and comparison of valved conduits used for right ventricular outflow tract reconstruction.

Read more ...